Hydroxylated metabolites of thalidomide: Formation in-vitro and in-vivo in man

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 12, 1998, Pages 1409-1416

  Eriksson, Tommy ^b   Björkman, Sven ^a   Roth, Bodil ^b   Björk, Henrik ^b   Höglund, Peter ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; THALIDOMIDE;

ACIDIFICATION; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COOLING; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STABILITY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER HOMOGENATE; NONHUMAN; NORMAL HUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET IRRADIATION;

EID: 0342720501     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb03368.x     Document Type: Article

References (27)

1. Blaschke, G., Hess, H. R., Lupke N.-P. (1989) Synthese und teratogene Wirkung von N-Hydroxythalidomide. Arzneim. Forsch. 39: 293-294
2. Boylen, J. B., Horne, H. H., Johnson, W. J. (1963) Teratogenic effects of thalidomide and its metabolites on the developing chick embryo. Can. J. Biochem. 42: 35-42
3. Braun, A. G., Weinreb, S. L. (1985) Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes. Teratog. Carcinog. Mutagen. 5: 149-158
4. Chen, T.-L., Vogelsang, G. B., Petty, B. G., Brundrett, R. B., Noe, D. A., Santos, G. W., Colvin, O. M. (1989) Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab. Dispos. 17: 402-405
5. Eriksson, T., Björkman, S. (1997) Handling of blood samples for determination of thalidomide. Clin. Chem. 43: 1094-1095
6. Eriksson, T., Björkman, S., Fyge, Å., Ekberg, H. (1992) Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J. Chromatogr. 582: 211-216
7. Eriksson, T., Björkman, S., Roth, B., Fyge, Å., Höglund, P. (1995) Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7: 44-52
8. Eriksson, T., Björkman, S., Roth, B., Fyge, Å., Höglund, P. (1998) The enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 10: 223-228
9. Fratta, I. D., Sigg, E. B., Moiorama, K. (1965) Teratogenic effects of thalidomide in rabbits, rats, hamsters and mice. Toxicol. Appl. Pharmacol. 7: 268-286
10. Gordon, G. B., Spielberg, S. P., Blake, D. A., Balasubramanian, V. (1981) Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl Acad. Sci. USA 78: 2545-2548
11. Gunzler, V. (1992) Thalidomide in human immunodeficiency virus (HIV) patients. Drug Safety 7: 116-134
12. Hatfill, S. J., Fester, E. D., De Beer, D. P., Bohm, L. (1991) Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites. Leukemia Res. 15: 129-136
13. Höglund, P., Eriksson, T., Björkman, S. (1998) A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J. Pharmacokin. Biopharm 26: 363-383
14. Knoche, B., Blaschke, G. (1994) Stereoselectivity of the in vitro metabolism of thalidomide. Chirality 6: 221-224
15. Koch, H. P. (1985) Thalidomide and congeners as anti-inflammatory agents. Prog. Med. Chem. 22: 165-242
16. Marwick, C. (1997) Thalidomide back - under strict control. J. Am. Med. Assoc. 278: 1135-1137
17. Neubert, R., Neubert, D. (1997) Peculiarities and possible mode of actions of thalidomide. Handb. Exp. Pharmacol. 124 (Drug Toxicity in Embryonic Development II): 41-119
18. Östraat, Ö., Riesbeck, K., Qi, Z., Eriksson, T., Schatz, H., Ekberg, H. (1996) Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro. Transplant. Immunol. 4: 117-125
19. Schuler, S., Ehninger, U. (1995) Thalidomide: rationale for renewed use in immunological disorders. Drug Safety 12: 364-369
20. Schumacher, H., Smith, R. L., Williams, R. T. (1965a) The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. 25: 324-337
21. Schumacher, H., Smith, R. L., Williams, R. T. (1965b) The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25: 338-351
22. Schumacher, H., Blake, D. A., Gillette, J. R. (1968) Disposition of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 160: 201-211
23. Schumacher, H. J., Wilson, J. G., Terapane, J. F., Rosedale, S. L. (1970) Thalidomide: disposition in rhesus monkey and studies of its hydrolysis in tissues of this and other species. J. Pharmacol. Exp. Ther. 173: 265-269
24. Smith, R. L., Williams, R. A. D., Williams, R. T. (1962) Phthaloylisoglutamine, a metabolite of thalidomide. Life Sci. 7: 333-336
25. Teubert, U., Zwingenberger, K., Wnendt, S., Eger, K. (1998) 5′-Substituted thalidomide analogs as modulators of TNF-α. Arch. Pharm. Pharm. Med. Chem. 331: 7-12
26. Weinz, C., Blaschke, G. (1995) Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis. J. Chromatogr. B 674: 287-292
27. Zwingenberger, K., Wnendt, S. (1996) Immunomodulation by thalidomide: systemic review of the literature and of unpublished observations. J. Inflamm. 46: 177-211